A Phase 2 interventional study of 5-FU and Bevacizumab in Colorectal Cancer, sponsored by Hoffmann-La Roche. Terminated at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 40th largest by enrollment of the 183 interventional ones that give a count, is one of 7 that started in 2014, is one of 110 in phase 2, and was the 160th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–70
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 130 · Phase 3 40 · Phase 4 5
First in 1998; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 50 across the 183 interventional studies. Of the 134 that completed or were terminated, 35 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 206 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 25th largest by enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2014, is one of 32 in phase 2, and was the 80th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
4 of the studies testing oxaliplatin in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233850Shenyang Sunshine Pharmaceutical Co., LTD.A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT06269978Arjun MittraIntraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 multicenter, randomized, parallel arms, double-blind study of vanucizumab to evaluate the efficacy and safety of vanucizumab in combination with oxaliplatin, folinic acid, and 5-fluorouracil (5-FU) (mFOLFOX-6) versus bevacizumab (Avastin) + mFOLFOX-6 in participants with previously untreated metastatic colorectal cancer (mCRC). The study consists of 2 parts: a safety run-in open-label, single-arm part (Part 1) and a randomized, parallel-arms, double-blind part (Part 2). During Part 1 at least 6 eligible participants will receive 2000 milligrams (mg) vanucizumab every 2 weeks + mFOLFOX-6 in order to confirm the dose and schedule that will be used in Part 2. In Part 2, all eligible participants will be randomized in a ratio of 1:1 to receive either mFOLFOX-6 + vanucizumab or mFOLFOX-6 + bevacizumab. Study treatment (induction and maintenance) will be given on Day 1 of each 14-day cycle. Induction therapy will consist of up to 8 cycles of mFOLFOX-6 plus either bevacizumab or vanucizumab. Maintenance therapy will consist of 5-fluorouracil and folinic acid plus either vanucizumab or bevacizumab for up to 24 months or until disease progression, unacceptable toxicity, Investigator decision or consent withdrawal, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m\^2) as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
Drug: 5-FU · Drug: Folinic acid · Drug: Oxaliplatin · Drug: Vanucizumab
Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
Drug: 5-FU · Drug: Folinic acid · Drug: Vanucizumab
Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m\^2 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
Drug: 5-FU · Drug: Bevacizumab · Drug: Folinic acid · Drug: Oxaliplatin
Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m\^2 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
Drug: 5-FU · Drug: Folinic acid · Drug: Oxaliplatin · Drug: Vanucizumab
Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
Drug: 5-FU · Drug: Bevacizumab · Drug: Folinic acid
Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
Drug: 5-FU · Drug: Folinic acid · Drug: Vanucizumab
5-FU will be administered according to dose and schedule described in respective arm.
Bevacizumab will be administered according to dose and schedule described in respective arm.
Also known as: Avastin
Folinic acid will be administered according to dose and schedule described in respective arm.
Oxaliplatin will be administered according to dose and schedule described in respective arm.
Vanucizumab will be administered according to dose and schedule described in respective arm.
Also known as: RO5520985
Progression-free Survival (PFS), Time to Event
Efficacy of vanucizumab was evaluated in terms of PFS as Investigator-Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). PFS was defined as the time between randomization and the date of first documented disease progression or death from any cause on study, whichever occurred first. Death on study was defined as death from any cause within 30 days of the last study treatment.
Time frame: Baseline, every 8 weeks, up to approximately 29 months
Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1
Efficacy of vanucizumab was evaluated in terms of Percentage of Participants With ORR as Investigator-Assessed Using RECIST v. 1.1. Best Overall Confirmed Response.
Time frame: Baseline (within 28 days prior to Day 1), then every 8 weeks until progressive disease (PD), start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)
Duration of Objective Response, as Assessed Using RECIST v. 1.1
Efficacy of vanucizumab was evaluated in terms of duration of objective response as assessed using RECIST v. 1.1. This was computed using the PFS definition with death on study (deaths that occurred outside the 30 days window from the last study treatment are excluded).
Time frame: Baseline (within 28 days prior to Day 1), then every 8 weeks until PD, start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)
Overall Survival (OS)
Efficacy of vanucizumab was evaluated in terms of OS as the time from randomization until death from any cause. 99999 = data not estimable due to the low number of deaths.
Time frame: Baseline until death from any cause (maximum up to approximately 3.5 years)
Percentage of Participants With Adverse Events (AEs)
Safety is evaluated in terms of percentage of participants with at least one serious adverse event and percentage of participants with at least one adverse event.
Time frame: Up to approximately 29 months
Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab
Safety is evaluated in terms of number of participants with Human Anti-human Antibodies (HAHAs) Against Vanucizumab.
Time frame: End of study (EoS, within 28 to 42 days after last dose, latest at 29 months)
Area Under the Plasma Concentration-Time Curve (AUC) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of AUC
Time frame: Cycles 1 and 8 of parts 1 and 2
Maximum Observed Plasma Concentration (Cmax) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of Cmax
Time frame: Cycles 1 and 8 of parts 1 and 2
Minimum Observed Plasma Concentration (Clast) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of Clast
Time frame: Cycles 1 and 8 of parts 1 and 2
Time to Reach Cmax (Tmax) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of Tmax
Time frame: Cycles 1 and 8 of parts 1 and 2
Plasma Terminal Half-Life (t1/2) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of t1/2, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
Time frame: Cycle 8
Plasma Clearance at Steady State (CLss) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of CLss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
Time frame: Cycle 8
Volume of Distribution at Steady State (Vss) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of Vss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
Time frame: Cycle 8
Cmax Accumulation Ratio (AR) of Vanucizumab
PK profile of vanucizumab was evaluated in terms of Cmax Ratio, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
Time frame: Cycle 8
| Milestone | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|---|
| Started | 8 | 94 | 95 |
| Completed | 2 | 0 | 0 |
| Not completed | 6 | 94 | 95 |
| Withdrew: Adverse event | 1 | 18 | 11 |
| Withdrew: Physician decision | 2 | 19 | 14 |
| Withdrew: Study terminated by sponsor | 0 | 6 | 6 |
| Withdrew: Non-compliance | 0 | 1 | 0 |
| Withdrew: Progressive disease | 3 | 32 | 50 |
| Withdrew: Reason not specified | 0 | 9 | 10 |
| Withdrew: Withdrawal by subject | 0 | 9 | 4 |
Efficacy of vanucizumab was evaluated in terms of PFS as Investigator-Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). PFS was defined as the time between randomization and the date of first documented disease progression or death from any cause on study, whichever occurred first. Death on study was defined as death from any cause within 30 days of the last study treatment.
| days | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|
| Progression-free Survival (PFS), Time to Event | 338.0 (312.0 to 381.0) | 309.0 (284.0 to 352.0) |
Efficacy of vanucizumab was evaluated in terms of Percentage of Participants With ORR as Investigator-Assessed Using RECIST v. 1.1. Best Overall Confirmed Response.
| Percentage of Participants | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|---|
| Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1 | 62.5 (34.3 to 90.6) | 43.6 (33.59 to 53.64) | 51.6 (41.53 to 61.63) |
Efficacy of vanucizumab was evaluated in terms of duration of objective response as assessed using RECIST v. 1.1. This was computed using the PFS definition with death on study (deaths that occurred outside the 30 days window from the last study treatment are excluded).
| days | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|
| Duration of Objective Response, as Assessed Using RECIST v. 1.1 | 342 (274 to 510) | 304 (220 to 366) |
Efficacy of vanucizumab was evaluated in terms of OS as the time from randomization until death from any cause. 99999 = data not estimable due to the low number of deaths.
| days | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|
| Overall Survival (OS) | 746.0 (687.0 to NA) | NA (723.0 to NA) |
Safety is evaluated in terms of percentage of participants with at least one serious adverse event and percentage of participants with at least one adverse event.
| Percentage of Participants | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|---|
| Serious Adverse events | 37.5 | 49.5 | 43.2 |
| Adverse events | 100 | 100.0 | 100.0 |
Safety is evaluated in terms of number of participants with Human Anti-human Antibodies (HAHAs) Against Vanucizumab.
| Participants | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab | 2 | 1 |
PK profile of vanucizumab was evaluated in terms of AUC
| hr*ug/ml | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Cycle 1 | 73600 ± 20.7 | 63500 ± 27.2 |
| Cycle 8 | 112000 ± 11.2 | 82100 ± 31.6 |
PK profile of vanucizumab was evaluated in terms of Cmax
| ug/ml | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Cycle 1 | 463 ± 18.5 | 500 ± 26.3 |
| Cycle 8 | 685 ± 17.6 | 794 ± 38.2 |
PK profile of vanucizumab was evaluated in terms of Clast
| ug/ml | Vanucizumab + mFOLFOX-6 |
|---|---|
| Cycle 1 | 103 ± 67.2 |
| Cycle 8 | 361 ± 39.8 |
PK profile of vanucizumab was evaluated in terms of Tmax
| hr | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Cycle 1 | 2.79 (1.50 to 7.67) | 2.05 (1.0 to 26.1) |
| Cycle 8 | 4.04 (0.5 to 5.25) | 1.58 (0.5 to 4.77) |
PK profile of vanucizumab was evaluated in terms of t1/2, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
| hr | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Plasma Terminal Half-Life (t1/2) of Vanucizumab | 202 ± 12.4 | 157 ± 30.3 |
PK profile of vanucizumab was evaluated in terms of CLss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
| ml/hr | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Plasma Clearance at Steady State (CLss) of Vanucizumab | 15.3 ± 26.7 | 18.0 ± 29.0 |
PK profile of vanucizumab was evaluated in terms of Vss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
| ml | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Volume of Distribution at Steady State (Vss) of Vanucizumab | 4400 ± 25.1 | 4140 ± 29.7 |
PK profile of vanucizumab was evaluated in terms of Cmax Ratio, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.
| Ratio | Safety Run-In | Vanucizumab + mFOLFOX-6 |
|---|---|---|
| Cmax Accumulation Ratio (AR) of Vanucizumab | 1.51 ± 27.2 | 1.63 ± 36.2 |
Collected over Up to 28 days after the last dose of study drug (maximum treatment time = approximately 29 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Run-In | 3/8 (37.5%) | 3/8 (37.5%) | 8/8 (100%) |
| Vanucizumab + mFOLFOX-6 | 24/93 (25.8%) | 46/93 (49.5%) | 91/93 (97.8%) |
| Bevacizumab + mFOLFOX-6 | 27/95 (28.4%) | 41/95 (43.2%) | 94/95 (98.9%) |
| Event | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/8 | 1/93 | 2/95 |
| Cardiac failureCardiac disorders | 1/8 | 0/93 | 0/95 |
| Intestinal obstructionGastrointestinal disorders | 1/8 | 3/93 | 3/95 |
| NauseaGastrointestinal disorders | 1/8 | 1/93 | 0/95 |
| VomitingGastrointestinal disorders | 1/8 | 1/93 | 1/95 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/8 | 0/93 | 5/95 |
| PyrexiaGeneral disorders | 0/8 | 4/93 | 4/95 |
| Urinary tract infectionInfections and infestations | 0/8 | 2/93 | 4/95 |
| Intestinal perforationGastrointestinal disorders | 0/8 | 3/93 | 2/95 |
| Large intestine perforationGastrointestinal disorders | 0/8 | 3/93 | 1/95 |
| Event | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/8 | 56/93 | 57/95 |
| NauseaGastrointestinal disorders | 6/8 | 52/93 | 55/95 |
| DysgeusiaNervous system disorders | 5/8 | 16/93 | 22/95 |
| HypertensionVascular disorders | 5/8 | 42/93 | 27/95 |
| NeutropeniaBlood and lymphatic system disorders | 4/8 | 40/93 | 43/95 |
| Mucosal inflammationGeneral disorders | 4/8 | 23/93 | 31/95 |
| AstheniaGeneral disorders | 3/8 | 41/93 | 42/95 |
| AnaemiaBlood and lymphatic system disorders | 3/8 | 6/93 | 12/95 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/8 | 4/93 | 8/95 |
| ConstipationGastrointestinal disorders | 3/8 | 26/93 | 31/95 |
| Age, Continuous(years) | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 | Total |
|---|---|---|---|---|
| Mean | 63.3 ± 10.8 | 62.7 ± 11.0 | 62.3 ± 10.6 | 62.5 ± 0.2 |
| Age, Customized(Participants) | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 | Total |
|---|---|---|---|---|
| Adults (18-64 years) | 4 | 48 | 53 | 105 |
| From 65-84 years | 4 | 46 | 42 | 92 |
| Sex: Female, Male(Participants) | Safety Run-In | Vanucizumab + mFOLFOX-6 | Bevacizumab + mFOLFOX-6 | Total |
|---|---|---|---|---|
| Female | 3 | 38 | 57 | 98 |
| Male | 5 | 56 | 38 | 99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2014 to primary completion in Jul 2016, 24 months.
Results were first posted in Mar 2020, 3 years 7 months after primary completion. A results delay was requested in Jan 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxaliplatin · Vanucizumab